Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Peter P. Tóth, MD, PhD Clinical Associate Professor Department of Family and Community Medicine University of Illinois College of Medicine Peoria, Illinois Director of Preventive Cardiology Sterling Rock Falls Clinic Sterling, Illinois
54
Embed
Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Peter P. Tóth, MD, PhD Clinical Associate Professor Department of Family and Community.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Dyslipidemia and Cardiovascular Risk Reduction:
An Evidence-Based ReviewPeter P. Tóth, MD, PhD
Clinical Associate ProfessorDepartment of Family and Community Medicine
University of Illinois College of MedicinePeoria, Illinois
Director of Preventive CardiologySterling Rock Falls Clinic
Sterling, Illinois
Key Question
What percentage of your patients withdyslipidemia who are receiving statin therapy alone achieve LDL goal?
Discuss current guidelines for the management of dyslipidemia
Describe the results of recent clinical trials relevant to the management of dyslipidemia
State lipid goals according to patients’ level of cardiovascular risk
Cardiovascular Disease (CVD)
Leading cause of death in the United States37% of all US deaths in 20031
Total US cost in 2006 = $403.1 billion1
Associated with high blood levels of cholesterol and other lipids, and low HDL levels1
Risk assessment, risk reduction1,2
HDL: high-density lipoprotein1. Thom T, et al. Circulation. 2006;113:e85-e151.2. NCEP ATP III. JAMA. 2001;285:2486-2497.
NCEP ATP III Risk Determinants
LDL level CHD or CHD risk equivalents:
Other clinical atherosclerotic diseaseDiabetesMultiple other risk factors contributing to a
Framingham 10-year risk of CHD >20% Other major risk factors
NCEP ATP III. JAMA. 2001;285:2486-2497.
NCEP ATP III: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)LDL: low-density lipoproteinCHD: coronary heart disease
Major Risk FactorsOther Than LDL and CHD
Cigarette smoking Hypertension
BP ≥140/90 mm Hg or on antihypertensive medication Low HDL level
<40 mg/dL Family history of premature CHD
Male first-degree relative <55 years Female first-degree relative <65 years
Age Men ≥45 years Women ≥55 years
BP: blood pressure
NCEP ATP III. JAMA. 2001;285:2486-2497.
Test OptimalBorderline High Risk
High RiskVery High
Risk
Total Cholesterol
<200 200-239 ≥240
LDL <100 130-159 160-189 ≥190
HDL ≥60 40-59 <40
Triglycerides <150 150-199 200-499 ≥500
NCEP ATP III Risk Definitions
NCEP ATP III. JAMA. 2001;285:2486-2497.
Risk Assessment:Dyslipidemia and CVD
Framingham risk calculator1,2 Based on age, sex, total and HDL
cholesterol, smoking, BP Mobile Lipid Clinic3
Free NCEP ATP III–based tools Palm® and Windows®
Reynolds risk calculator4
For healthy women without diabetes
1. Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). Available at http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof. Accessed on January 17, 2007.
2. Grundy SM, et al. J Am Coll Cardiol. 1999;34:1348-1359.3. Mobile Lipid Clinic. Available at http://www.mobilelipidclinic.com/DesktopDefault.aspx. Accessed on
January 17, 2007.4. Reynolds Risk Score. Available at http://www.reynoldsriskscore.org/default.aspx. Accessed on
February 23, 2007.
NCEP ATP III Risk Categories
Risk Category Criteria
Low risk 0-1 risk factor
Moderate risk≥2 risk factors;
10-year risk <10%
Moderately high risk≥2 risk factors;
10-year risk 10%-20%
High riskCHD or CHD risk equivalents;
10-year risk >20%
Grundy SM, et al. Circulation. 2004;110:227-239.
Dyslipidemia
Presence of abnormal levels of blood lipids and lipoproteins1
Diagnosed using fasting lipoprotein profile1
Nearly 40% of US adults have LDL levels ≥130 mg/dL (borderline high or higher)2
1. NCEP ATP III. JAMA. 2001;285:2486-2497.2. Thom T, et al. Circulation. 2006;113:e85-e151.
Key Question
Why do so many patients have high lipid levels?
1. Lack of screening and treatment by clinicians
2. Lack of effective medications
3. Lack of therapy adherence by patients
4. 1 and 3
5. All of the above
Use your keypad to vote now!
?
Problem: Low Success Rates in Achieving Lipid Goals
0
10
20
30
40
50
60
70
80
Overall Low risk High risk CHD
% at goal
Pearson TA, et al. Arch Intern Med. 2000;160:459-467.
% P
atie
nt
Su
cces
s
Risk Groups
Problem: Patients’ Adherence to Statin Therapy
0
10
20
30
40
50
60
70
80
90
100
9 Months 12 Months
Huser MA, et al. Adv Ther. 2005;22:163-171.
Ove
rall
Per
sist
ence
(%
)
NCEP Guidelines in a Nutshell
Identify individuals at high risk of CV events: 10-year risk >20%10-year risk 10%-20%
Start therapeutic lifestyle changes and/or medication Adjust intensity of therapy to individual risk level Monitor progress to goal lipid control
Adherence is always a factor
NCEP ATP III. JAMA. 2001;285:2486-2497.
CV: cardiovascular
NCEP ATP III 2001Thresholds for LDL-Lowering Therapy
TLC(mg/dL)
Consider Drug Therapy (mg/dL)
Low Risk 0-1 risk factor ≥160≥190
(optional at 160-189)
Moderate Risk2 risk factors;
10-year risk <10% ≥130 ≥160
Moderately High Risk
2 risk factors; 10-year risk 10%-20%
≥130≥130
(optional at 100-129)
High RiskCHD or CHD risk
equivalents;10-year risk >20%
≥100≥130≥100
(optional at <100)
TLC: therapeutic lifestyle changes
1. NCEP ATP III. JAMA. 2001;285:2486-2497.2. Grundy SM, et al. Circulation. 2004;110:227-239.
NCEP ATP III Thresholds:Update 2004
Very high-risk patients LDL ≥100 mg/dL consider drug therapy LDL goal <70 mg/dL a therapeutic option
Moderately high-risk patients LDL goal <100 mg/dL a therapeutic option
High-risk and moderately high-risk patients 30%-40% reduction in LDL recommended
High-risk patients with high TG or low HDL levels Consider fibrate or nicotinic acid
High-risk or moderately high-risk patients with lifestyle-related risk factors Therapeutic lifestyle change regardless of LDL
Grundy SM, et al. Circulation. 2004;110:227-239.
TG: triglyceride
NCEP ATP IIITherapeutic Goals for LDL
Risk Category LDL Goal (mg/dL)
Low risk0 to 1 risk factor
<160
Moderate risk2 risk factors; 10-year risk <10%
<130
Moderately high risk2 risk factors; 10-year risk 10%-20%
<130(optional goal <100)
High riskCHD or CHD risk equivalents; 10-year risk >20%
<100(optional goal <70 for very
high-risk patients)
1. NCEP ATP III. JAMA. 2001;285:2486-2497.2. Grundy SM, et al. Circulation. 2004;110:227-239.
Review of Key Clinical Trials Conducted in 2005
Persons with diabetes and CHD should be treated aggressively with statins, even if they are not otherwise at high risk
The first line of therapy should continue to be statins rather than fibrates (which are still useful in combination therapy)
BP (mm Hg) Systolic ≥130 or diastolic ≥85 Systolic ≥130 or diastolic ≥85
Fasting Plasma Glucose (mg/dL)
≥100 ≥100
1. Grundy SM, et al. Circulation. 2005;112:2735-2752.2. International Diabetes Federation. Rationale for new IDF worldwide definition of metabolic syndrome. Available at http://www.idf.org/webdata/docs/Metabolic_syndrome_rationale.pdf. Accessed on February 3, 2007.
IDF: International Diabetes Federation
Prevalence of Metabolic Syndrome: NHANES III 1988-1994
0
10
20
30
40
50
MenWomen
Per
cen
t A
ffec
ted
20-29 30-39 40-49 50-59 60-69 70+Age (years)
Ford ES, et al. JAMA. 2002;287:356-359.NHANES III: Third National Health and Nutrition Examination Survey
Metabolic Syndrome Prevalence by Race and Ethnicity
0
5
10
15
20
25
30
35
40
Men Women
White
African American
Mexican American
Other
% A
ffec
ted
Ford ES, et al. JAMA. 2002;287:356-359.
Pattern of Dyslipidemia in Type 2 Diabetes
Triglycerides HDL Qualitative changes in LDL
Higher proportion of smaller and denser LDL particles susceptible to oxidation and atherogenicity
Mean LDL levels not different in high-risk patients with or without diabetes, but important risk factor
Haffner SM. Diabetes Care. 2004;27(suppl 1):S68-S71.
Prevalence of Dyslipidemia in Patients With Type 2 Diabetes
0
10
20
30
40
50
60
70
Aff
ecte
d (
%)
Total C≥200 mg/dL
LDL-C≥100 mg/dL
HDL-C40 mg/dL
Triglycerides≥150 mg/dL
C: cholesterol
Saaddine JB, et al. Ann Intern Med. 2006;144:465-474.
American Diabetes Association Lipid Treatment Goals
Decrease triglycerides to <150 mg/dL Increase HDL to >40 mg/dL in men and >50 mg/dL in women
Diabetes without overt CVD Diabetes with overt CVD
LDL <100 mg/dL30%-40% reduction with
statin for patients >40 years, regardless of baseline LDL
LDL <70 mg/dL an option30%-40% reduction with statin
therapy for all patients
American Diabetes Association. Diabetes Care. 2006;29(suppl 1):S4-S42.
Therapeutic Lifestyle Changes
Adherence to 5 healthful lifestyles reduced coronary events by ≈62% in 16 years
Lifestyle changes reduced coronary events by 57% in men taking medications for HTN or dyslipidemia
Men who adopted 2 lifestyle changes had 27% lower risk than those who did not
HTN: hypertension
Chiuve SE, et al. Circulation. 2006;114:160-167.
LIFESTYLE CHANGES Eliminate tobacco exposure Body mass index <25 kg/m2
30 min/d physical activity Limit alcohol use to 1-2
More high-risk patients reached their LDL target of <100 mg/dL with rosuvastatin (10 or 20 mg/d) than with atorvastatin (10 or 20 mg/d) or simvastatin (20 or 40 mg/d)
Likewise, more patients at very high risk reached their LDL goal of <70 mg/dL with rosuvastatin than with atorvastatin or simvastatin
Ballantyne CM, et al. Am Heart J. 2006;151:975.e1-975.e9.
MERCURY II: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY
Other Lipid-Lowering Drugs
Fibrates can decrease triglycerides and increase HDL levels1-3
Niacin (nicotinic acid) can also decrease triglycerides and increase HDL levels1-3
Ezetimibe can further decrease LDL levels by selectively inhibiting intestinal absorption of cholesterol1,3
Bile acid sequestrants may decrease LDL1-3
Combination therapy may be effective1,3
1. Treat Guidel Med Lett. 2005;3:15-22.2. NCEP ATP III. JAMA. 2001;285:2486-2497.3. Grundy SM, et al. Circulation. 2004;110:227-239.
NCEP ATP IIIDrug Therapy Progression
NCEP ATP III. JAMA. 2001;285:2486-2497.
6 wk 4-6 mo
If goal not met, intensify drug
therapy
6 wk
If goal not met, intensify drug
therapy or refer to lipid
specialist
Begin drug therapy to
decrease LDL
Continue to monitor
response and adherence
Improving Patients’ Adherence
Simplify medication regimensPrescribe fewer pills per day1
Avoid medication switching2
Help patients remember to take medicationsTime pills with events like meals, bedtime3
Recommend pill boxes, personal alarms Teach patients about risks and benefits
Offer educational tools, brochures, Web sitesUse follow-up lipid tests to monitor progress4
1. Iskedjian M, et al. Clin Ther. 2002;24:302-316. 2. Thiebaud P, et al. Am J Manag Care. 2005;11:670-674.3. Branin JJ. Home Health Care Serv Q. 2001;20:1-16.4. Benner JS, et al. Pharmacoeconomics. 2004;22(suppl 3):13-23.
Improving Patients’ Adherence
Medication adherence drops as costs rise1
Ask if patients have prescription drug coverage Identify generic or preferred drugs Urge patients to raise cost problems over time
Depression can reduce adherence2
Look for and ask about signs of depression Treat and/or refer depressed patients
for counseling
1. Shrank WH, et al. Arch Intern Med. 2006;166:332-337.2. Stilley CS, et al. Ann Behav Med. 2004;27:117-124.
Share Decision Making
A patient-clinician partnership based on mutual respect and trust improves medication adherenceAsk patients how they understand their condition
and the need to treat itListen and probe for perceived barriersCustomize your suggestions to their needsEnlist family members as advocates
Piette JD, et al. Arch Intern Med. 2005;165:1749-1755.
Case Study
Case Study
76-year-old white nonsmoking woman History of hypertension, depression Current medications:
Diltiazem 240 mg qdNefazodone 150 mg bid
Examination: Height 5′6″; weight 146 lb; BMI 23.6 kg/m2; BP 139/82 mm Hg; pulse 72 bpm
BMI: body mass index
Laboratory Results
Creatinine: 1.4 mg/dL Lipid panel
Total cholesterol: 245 mg/dLLDL: 156 mg/dLHDL: 59 mg/dLTriglycerides: 148 mg/dL
ATP III: Framingham Point Scores to Estimate 10-Year Risk
Therapeutic lifestyle changesFirst line of treatment Include dietary modification, exercise,
and weight control Lipid-lowering medications1,2
Statins are safe and effective,3-5 and significantly reduce risk of CVD and stroke6-8
Other agents (eg, fibrates, niacin)9
1. Grundy SM, et al. Circulation. 2004;110:227-239.2. Stone NJ, et al. Am J Cardiol. 2005;96:53E-59E.3. Deedwania P, Volkova N. Expert Rev Cardiovasc Ther. 2005;3:453-463.4. Helmy T, et al. MedGenMed. 2005;7:8.5. Pohlel K, et al. Curr Opin Lipidol. 2006;17:54-57.
6. NCEP ATP III. JAMA. 2001;285:2486-2497.7. Heart Protection Study Collaborative Group. Lancet. 2002;360:7-22.8. Shepherd J, et al. Lancet. 2002;360:1623-1630.9. Rubins HB, et al. N Engl J Med. 1999;341:410-418.
Therapeutic Considerations
Drug interactionsCalcium channel blockers1
Antidepressants2
Others (eg, warfarin)3
Comorbid conditions Regular monitoring of hepatic, renal function
Decreased renal function
1. Herman RJ. CMAJ. 1999;161:1281-1286. 2. Karnik NS, Maldonado JR. Psychosomatics. 2005;46:565-568. 3. Treat Guidel Med Lett. 2005;3:15-22.
Special Populations
Women1
CHD delayed 10 to 15 years versus men Premature CHD risk associated with multiple
risk factors and metabolic syndrome Treatment approach should be similar for
women and men African Americans1
Highest overall CHD mortality rate Asian Indians2,3
Increased risk of metabolic syndrome and CHD versus whites
1. NCEP ATP III. JAMA. 2001;285:2486-2497.2. Misra A, Vikram NK. Curr Sci. 2002;83:1483-1494.3. Enas EA, et al. Indian Heart J. 1996;48:343-353.
Conclusions
Improving patients’ adherence will improve clinical outcomes
Optimal results require both lifestyle and medical interventions
Lipid-lowering therapy must be tailored to the individual patientRisk determines lipid goalsComorbid conditions influence treatment
Q & A
PCE Takeaways
PCE Takeaways
1. Use risk calculation tools
2. Identify appropriate goals based on risk… and treat to goal!
3. Appreciate the unique profile of diabetic patients with dyslipidemia
4. Address common barriers to adherence and modify treatment regimen accordingly
Key Question
How important are the IVUS data when conveying information linking medical treatment to atherosclerosis regression to patients?